Nov 07, 2019
NetNoggin® releases exploratory analysis "Healthcare Provider Needs in the NASH Market"
Oct 30, 2019
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
Oct 30, 2019
PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019
Oct 26, 2019
HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)
Oct 22, 2019
HighTide Therapeutics Announces Completion of Enrollment in Phase 2a NASH Study of HTD1801
Oct 21, 2019
B. Riley FBR to Host NASH Symposium in San Francisco on October 24, 2019
Oct 16, 2019
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
Oct 10, 2019
Data to be Presented at AASLD 2019 Shows HighTide Lead Compound Improves NASH in Two Animal Models
Oct 03, 2019
Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight(TM) Human Liver Disease platform
Oct 03, 2019
Zydus Announces Positive Results From EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH
Sep 26, 2019
Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis
Sep 25, 2019
89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent
Aug 29, 2019
Global $61.6 Bn Non-Alcoholic Steatohepatitis (NASH) Drugs Market to 2028
Aug 27, 2019
Ascletis Received IND Approval for its NASH Drug
Aug 08, 2019
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
Aug 05, 2019
3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing
Jul 29, 2019
Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5
Jul 02, 2019
HighTide Therapeutics Expands Leadership Team with Appointment of Adrian M. Di Bisceglie, M.D., as Chief Medical Officer
Jun 24, 2019
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Jun 19, 2019
High Point Clinical Trials Center Joins ProSciento's NASH PASS(TM) Initiative Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment